• Tue news: Pfizer explores sale of hospital drugs unit. FDA declines full approval of Ocaliva. AZ better than expected Q3 results. Pfizer, Lilly telehealth platforms draw scrutiny. 23andMe cutting lays off 40%. See more on our front page

Another ho hum ASCO for Amgen

anonymous

Guest
For as good as WE think we are the rest of the oncology community sure doesn't think so. Amgen made no waves or impact at all and was barely mentioned in news updates or more importantly by our customers. We will never be a real player in therapeutic oncology. It was embarrassing. Even our booth was a joke compared to most of the other companies. Truly sad...
 




For as good as WE think we are the rest of the oncology community sure doesn't think so. Amgen made no waves or impact at all and was barely mentioned in news updates or more importantly by our customers. We will never be a real player in therapeutic oncology. It was embarrassing. Even our booth was a joke compared to most of the other companies. Truly sad...

Amgen needs more than kyprolis and vectibix